6 citations
,
December 2020 in “Biological & Pharmaceutical Bulletin” Compounds from Eclipta prostrata L. plant have diabetes and obesity-fighting properties and reduce inflammation.
5 citations
,
January 1995 in “Journal of Dermatological Treatment” Calcipotriol does not improve the effectiveness of squaric acid dibutylester in treating alopecia areata.
8 citations
,
January 2019 in “Annals of Dermatology” Bilobetin may help reduce acne by decreasing sebum production.
October 2008 in “Clin-alert” Certain medications can reduce mortality risk in COPD patients, but others can increase risks of cardiovascular issues, postoperative delirium, and other adverse effects.
19 citations
,
March 2010 in “Steroids” Certain progesterone derivatives can inhibit enzymes and reduce androgenic activity, potentially affecting prostate growth.
1 citations
,
January 2025 in “CPT Pharmacometrics & Systems Pharmacology” Ritlecitinib effectively regrows eyebrow and eyelash hair in alopecia areata, with 50 mg being the best dose.
7 citations
,
September 2017 in “Pharmacoepidemiology and Drug Safety” The use of Diane-35 and its generics significantly decreased in the Netherlands.
13 citations
,
May 2007 in “Journal of Endocrinology” Synthetic 19-norprogestins promote bone cell growth and function through their non-phenolic metabolites.
November 2008 in “Cancer Prevention Research” Chemoprevention can significantly lower cancer risks and needs more research and collaboration.
April 2020 in “Research Square (Research Square)” Women with PCOS may have a reduced ability to fight breast tumor cells over time.
20 citations
,
January 2003 in “Chemical and Pharmaceutical Bulletin” The new progesterone derivatives effectively inhibit 5α-reductase and bind to the androgen receptor.
December 1982 in “PubMed” Hormonal contraceptives are highly effective but require medical evaluation due to potential health risks.
36 citations
,
July 1980 in “Journal of Toxicology and Environmental Health” High doses of ethynylestradiol in rats caused growth issues, organ changes, and some tumors, but didn't increase overall tumor rates.
1 citations
,
November 2019 in “Archives of breast cancer” Some hormone treatments might raise breast cancer risk, while others don't seem to.
4 citations
,
May 2023 in “Cells” Baricitinib and its combination with lonafarnib improve fat cell formation in certain genetic disorders.
November 2024 in “SKIN The Journal of Cutaneous Medicine” Baricitinib is widely used for several conditions, especially COVID-19, but its safety and effectiveness are still being evaluated.
June 2010 in “Melanoma research” LDE225 is a promising skin-applied treatment for basal cell carcinoma with good skin penetration and effectiveness.
4 citations
,
July 2024 in “Pharmacology Research & Perspectives” Ritlecitinib is safe and may effectively treat alopecia areata.
2 citations
,
July 2023 in “Cochrane Database of Systematic Reviews” The effectiveness of statins for women with PCOS is unclear.
39 citations
,
September 2000 in “Obstetrics and Gynecology Clinics of North America” Insulin-lowering medications show promise for PCOS symptoms but can't be the main treatment yet due to limited long-term research.
2 citations
,
January 2013 in “Iraqi journal of Medical Sciences” 18 citations
,
December 2005 in “Journal of Medicinal Chemistry” A brominated phenoxy compound effectively inhibits a human enzyme and shows potential for clinical use.
81 citations
,
February 2000 in “Anti-cancer drugs” Doxil showed some effectiveness against advanced prostate cancer but caused severe side effects at higher doses.
431 citations
,
October 2008 in “Current Medicinal Chemistry” Coumarin derivatives show promise as anti-estrogenic agents for treating breast cancer, with some in clinical trials.
The combination of high-dose toremifene and capecitabine was effective for advanced recurrent breast cancer.
45 citations
,
July 2025 in “Journal of Medicinal Chemistry” Vepdegestrant may become the first FDA-approved PROTAC degrader, marking a new era in drug development.
8 citations
,
April 2022 in “Revista Brasileira Ginecologia e Obstetrícia” Combined oral contraceptives are recommended for managing PCOS symptoms, but choices should be personalized.
1 citations
,
November 2023 in “SKIN The Journal of Cutaneous Medicine”
2 citations
,
February 2022 in “Frontiers in Endocrinology” Antiandrogenic pretreatment for women with PCOS does not improve fertility outcomes and delays pregnancy.
February 2020 in “İstanbul medical journal” Metformin improves early signs of heart disease in women with PCOS and raises apelin levels, but doesn't significantly change artery thickness.